Regeneron halting higher doses in fasinumab trials

In its 1Q18 earnings, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab (REGN475). Regeneron will

Read the full 270 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE